Management Team:

VIJAY B. SAMANT (Chief Executive Officer, Director) 

  • President and Chief Executive Officer, Vical Incorporated, 2000-2019 

  • Chief Operating Officer, Merck Vaccine Division, 1998-2000 

  • Contributed to the development of Vaqta® (Hepatitis A vaccine), Varivax® (chickenpox vaccine), Liquid PedvaxHIB ® (Hib vaccine) and Comvax® (combination vaccine of Hib and hepatitis B), Zostavax® (shingles vaccine), Aldurazyme® (mucopolysaccharidosis I), and Procysbi® (nephropathic cystinosis)

ZOLTAN SZEKELY, Ph.D. (Chief Technology Officer) 

  • Member and Chemist Co-investigator with Dr. Bertino at The Cancer Institute of New Jersey, 2014-present 

  • Generated IP for ADC toxins at National Cancer Institute, 1996-2006 

  • Co-inventor of Matriptimab™ antibody

LARRY R. SMITH, Ph.D. (Vice President of Development)

  • Senior VP Research, Vical Incorporated, 2003-2019 

  • Advanced several product candidates from preclinical studies to first-in-human Phase 1 trials  

  • Participated in 20 Phase 1 - Phase 3 clinical trials 

  • Director Viral Vaccines Immunology, Wyeth/Pfizer

ROBERT BAIN (Vice President of Business Development) 

  • Chief Commercial Officer and Co-founder of PARx Solutions, Inc.  

  • Executive Vice President of Business Development with Publicis Healthcare Communication Group 

  • Director, Business Development, Managed Markets, Bristol-Myers Squibb